Mitomics entered into a nonexclusive licensing agreement with QDx Pathology Services to develop, market, and process the QPredict™ Prostate Mitomic Test. The product will be based on the mitochondrial marker behind Mitomics’ currently marketed Prostate Core Mitomic Test™ (PCMT™).
QDx is a full-service clinical and anatomic pathology laboratory. It will leverage its existing network of urologists, pathologists, and processing centers to expand the availability of the technology across the U.S.
QDx is Mitomics’ first marketing partner. “Since the launch of PCMT in late March, our marketing strategy has focused on both direct sales and partnerships to achieve the widest product distribution possible,” says Robert Poulter, president and CEO of Mitomics.
PCMT determines the absence or presence of cancerous cells using prostate biopsy tissue and its cancerization field effect to identify molecular changes and enable detection of missed tumors. In a study published by Mitomics in the January 2010 issue of Prostate Cancer and Prostatic Diseases, the firm reported that PCMT’s sensitivity is 84% and that it has a negative predictive value of 91%.